美国多中心789例超米兰标准肝癌肝移植结局分析
美国20中心2002-2013年回顾性队列纳入超米兰标准肝癌肝移植患者789例,分析降期、局部治疗与生存及复发关系。降期成功者移植后结局良好,降期预测因素包括等待时间>12个月、甲胎蛋白对局部治疗的反应及肿瘤负荷;局部治疗未降期者复发风险高于未治疗者。
要点
- 超米兰标准肝癌经局部治疗成功降期者移植后5年生存与无复发生存较好。
- 降期预测因素包括甲胎蛋白对局部治疗反应、病理肿瘤数目与大小及等待时间>12个月。
- 局部治疗未降期者肝癌复发风险高于未治疗者,提示局部治疗可能加重不良肿瘤生物学。
核心结论
- 超米兰标准肝癌患者经局部治疗成功降期后肝移植结局良好,支持扩大肝移植标准。
- 局部治疗未降期者肝癌复发风险高于未治疗者,且不能由临床病理差异解释,提示局部治疗可能加重不良肿瘤生物学。
研究设计与样本
- 美国多中心肝癌肝移植联盟20个中心2002-2013年回顾性队列研究,纳入超米兰标准肝癌肝移植患者789例。
- 比较米兰标准内3570例与超米兰标准789例(降期465例、局部治疗未降期242例、未治疗82例)的临床病理特征及移植后结局。
主要发现
- 米兰标准内患者移植后5年总生存率和无复发生存率分别为71.3%和68.2%,高于降期组(64.3%和59.5%)和未降期组(60.2%和53.8%),总体P<0.001。
- 降期组较未降期组无复发生存率更优(60% vs. 54%,P=0.043),5年肝癌复发率更低(18% vs. 32%,P<0.001)。
- 按最大影像学肿瘤直径分层,降期且<5 cm者5年肝癌复发率为15.5%,未降期且>5 cm者为39.1%,P<0.001。
- 局部治疗未降期组肝癌复发率高于未治疗组(34.1% vs. 26.1%,P<0.001),控制临床病理变量后HR=2.33(P<0.001),倾向性评分加权匹配后HR=1.82(P<0.001)。
关键数值与推荐
- 降期的多因素预测因素包括甲胎蛋白对局部治疗的反应、病理肿瘤数目和大小、等待时间>12个月。
临床怎么用
- 对超米兰标准肝癌患者,可依据甲胎蛋白对局部治疗反应、肿瘤负荷和等待时间评估降期可能性,成功降期者可考虑肝移植。
- 局部治疗未降期者移植后复发风险较高,需谨慎选择并加强术后监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The Organ Procurement and Transplantation Network recently approved liver transplant (LT) prioritization for patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are down-staged (DS) with locoregional therapy (LRT). We evaluated post-LT outcomes, predictors of down-staging, and the impact of LRT in patients with beyond-MC HCC from the U.S. Multicenter HCC Transplant Consortium (20 centers, 2002-2013). APPROACH AND RESULTS: Clinicopathologic characteristics, overall survival (OS), recurrence-free survival (RFS), and HCC recurrence (HCC-R) were compared between patients within MC (n = 3,570) and beyond MC (n = 789) who were down-staged (DS, n = 465), treated with LRT and not down-staged (LRT-NoDS, n = 242), or untreated (NoLRT-NoDS, n = 82). Five-year post-LT OS and RFS was higher in MC (71.3% and 68.2%) compared with DS (64.3% and 59.5%) and was lowest in NoDS (n = 324; 60.2% and 53.8%; overall P < 0.001). DS patients had superior RFS (60% vs. 54%, P = 0.043) and lower 5-year HCC-R (18% vs. 32%, P < 0.001) compared with NoDS, with further stratification by maximum radiologic tumor diameter (5-year HCC-R of 15.5% in DS/<5 cm and 39.1% in NoDS/>5 cm, P < 0.001). Multivariate predictors of down-staging included alpha-fetoprotein response to LRT, pathologic tumor number and size, and wait time >12 months. LRT-NoDS had greater HCC-R compared with NoLRT-NoDS (34.1% vs. 26.1%, P < 0.001), even after controlling for clinicopathologic variables (hazard ratio [HR] = 2.33, P < 0.001) and inverse probability of treatment-weighted propensity matching (HR = 1.82, P < 0.001). CONCLUSIONS: In LT recipients with HCC presenting beyond MC, successful down-staging is predicted by wait time, alpha-fetoprotein response to LRT, and tumor burden and results in excellent post-LT outcomes, justifying expansion of LT criteria. In LRT-NoDS patients, higher HCC-R compared with NoLRT-NoDS cannot be explained by clinicopathologic differences, suggesting a potentially aggravating role of LRT in patients with poor tumor biology that warrants further investigation.
引用
- Kardashian A, Florman SS, Haydel B, et al. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria. Hepatology. 2020. PMID: 32124453. doi:10.1002/hep.31210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。